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Skin cancers are an incredibly common malignancy in the United States. A direct relationship 
between lifetime ultraviolet radiation and subsequent development of skin cancers has been 
established. Of these, non-melanoma skin cancers, including squamous cell carcinoma and 
basal cell carcinoma, are the most common. Cutaneous squamous cell carcinomas (cSCCs) 
located on the lip are concerning given their increased risk of recurrence and metastasis. Given 
this increased risk of morbidity and mortality, it is essential to continue to monitor patients 
with a history of these high-risk skin cancers with at least annual full-body skin exams. This 
study identified approximately 25% of patients without any follow-up for a skin check. This list 
was then securely provided to office staff to prioritize contacting these patients for follow-up.  
 
INTRODUCTION 
Currently, it is estimated that one in five Americans will develop skin cancer throughout 
their lifetime, with approximately 1 million new skin cancer cases occurring in the United States 
alone each year (Rigell, 2008). Non-melanoma skin cancers including cutaneous squamous cell 
carcinoma (cSCC) and basal cell carcinoma compromise the majority of these skin cancers 
(Clayman et al, 2005). Most cSCCs have a good overall prognosis and are easily cured by surgical 
excision or other local methods, however, a subset demonstrate propensity for higher risk of 
morbidity and mortality, including cSCC of the lip (Mullen et al, 2006). One study demonstrated 
that cSCC of the lip have an elevated risk of metastasis of 14%. This is compared to a baseline 
risk of approximately 5% for cSCC occurring on other sun-exposed areas (Rowe et. al, 1992). 
Research has also demonstrated patients diagnosed with a non-melanoma skin cancer have a 
40.7% 5-year probability and a 59.6% 10-year probability of developing a subsequent skin 
cancer (Wehner et al, 2015). Given these risks, it is important to have continuous follow-up to 
continue surveillance of high-risk skin cancer patients and to identify future skin cancers that 
may occur. A guideline published in 2017 for care of cSCC recommends at least yearly in-office 
screening skin exams by a dermatologist, adjusting this frequency based on individual risk (Alam 
et al, 2018). Therefore, it is important to identify patients with a history of high-risk cSCC, and 
ensure they are receiving annual full body skin exams as recommended for thorough 
surveillance of skin cancer recurrence and/or metastasis. This project aimed to improve cancer 
surveillance by the UVMMC Division of Dermatology for patients with cSCC of the lip, a high-risk 
skin cancer, particularly in the setting of delayed follow-up of care in the setting of the novel 
COVID-19 pandemic.  
 
METHODS 
This study was a quality improvement study conducted at the University of Vermont 
Medical Center Division of Dermatology. This study was conducted in the time of wide-spread 
office closure in the setting of the novel COVID-19 pandemic. Exclusion criteria included patient 
death and patients with more than one skin cancer type. A manual chart review was conducted 
of 244 cSCCs of the lip. Of these, 193 unique patients with cSCC of the lip were included in the 
study. Patients were further divided into two groups: those who had their SCC site evaluated by 
a UVMMC dermatology physician or PA within the past year (since 2/20/2019) and those who 
had not been seen in the past year (since 2/20/2019). These individuals were further classified 
by those who follow-up primarily with our office for skin checks and those who primarily follow-
up with an outside provider or non-dermatologic specialty for skin checks. Following 
identification of individuals with prior cSCC of the lip who had not received a full-body skin 
exam at our clinic within the past year, this list was then securely provided to office staff at the 
University of Vermont Medical Center Dermatology Office to prioritize these high-risk skin 
cancer patients following the return to clinical duties of dermatologic providers.  
 
RESULTS 
Refer to figure 1 for further clarification of exclusion and inclusion criteria. Overall, 36 
patients were identified as deceased. These patient deaths were unrelated to their skin cancer 
history. Additionally, 15 patients were identified as having more than one type of skin cancer. 
Furthermore, 27.5% of patients were identified as having follow-up at UVMMC within the next 
year. This is artificially low as many appointments are scheduled 1-3 months in advance. In 
addition, 40.5% of patients see an outside dermatologist and 12% see a non-dermatologic 
provider for skin checks. Many patients are referred to UVMMC for definitive surgery through 
our Mohs Department and then return to the referring provider for continued care, as is 
standard practice. We identified 25% of patients with no known appropriate follow-up. These 
records were manually reviewed to determine if the patient appears overdue for cancer 
surveillance. If this was the case, they were offered a priority follow-up appointment at the 
time of office re-opening.  
 
DISCUSSION  
In the setting of the novel COVID-19 pandemic, offices across the United States 
experienced closure for the health of providers and patients and to further implement a plan 
for safe practices. These closures and wide-spread fear of illness is likely to have resulted in 
delayed presentation to care and/or delayed patient follow-up. Given the need for regular in-
person follow-up of patients with high-risk skin cancer, it is prudent to identify patients that 
were overdue for skin cancer screening. This quality improvement study helped identify 
patients with high-risk cSCC that were overdue for dermatologic cancer surveillance. We then 
used cancer risk-stratification to assist office staff in prioritization of high-risk patient 
scheduling. A limitation of this study was that it did not track patients after initial identification 
to determine if patients were more likely to follow-up in our clinic following contact by staff. 
Future studies would be beneficial to determine if this study resulted in improved patient 
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